0001299130 false 0001299130 2022-10-25 2022-10-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares






Washington, DC 20549






Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934


Date of Report (Date of earliest event reported)

October 25, 2022


Pacific Biosciences of California, Inc.

(Exact name of registrant as specified in its charter)


Delaware   001-34899   16-1590339
(State or other jurisdiction
of incorporation)
File Number)
  (IRS Employer
Identification No.)


1305 O’Brien Drive

Menlo Park, California 94025

(Address of principal executive offices) (Zip Code)


(650) 521-8000

(Registrant’s telephone number, including area code)


(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


 ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class   Trading
  Name of each exchange
on which registered
Common Stock, par value $0.001 per share   PACB   The NASDAQ Stock Market LLC


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company ¨


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨






Item 2.02.Results of Operations and Financial Condition.


On October 25, 2022, Pacific Biosciences of California, Inc. (the “Company”) issued a press release announcing that it is withdrawing all of its previously announced financial guidance in connection with certain product announcements. The Company anticipates giving further updates on its third quarter earnings release and earnings call. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.


This information, as well as Exhibit 99.1, is intended to be furnished under Item 2.02 of Form 8-K, “Results of Operations and Financial Condition” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.




(d) Exhibits.
99.1 Press Release dated October 25, 2022 (furnished and not filed herewith solely pursuant to Item 2.02).

104 Cover Page Interactive Data File (embedded within the Inline XBRL document).







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



  Pacific Biosciences of California, Inc.
  By: /s/ Michele Farmer
    Michele Farmer
    Vice President and Chief Accounting Officer
Date: October 25, 2022    




    Exhibit 99.1



PacBio to Report Third Quarter Earnings on November 7 and Host Inaugural Investor Day on November 15.


Withdraws Guidance with New Product Announcement


MENLO PARK, Calif., October 25, 2022 – PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2022 financial results on Monday, November 7, 2022, at 5:00 pm Eastern Time.


PacBio will also host its Inaugural Investor Day on Tuesday, November 15, 2022, at 8:00 am Eastern Time. The event will feature presentations by members of PacBio's executive team and include Q&A sessions.


Both events will be webcast live and may be accessed at PacBio’s website at: https://investor.pacificbiosciences.com/.


Third Quarter Earnings Details


Date: Monday, November 7, 2022 at 5:00pm ET (2:00pm PT)

Listen live via internet or replay: https://investor.pacificbiosciences.com/

Toll-free: 866-652-5200

International: 412-317-6060


If using the dial-in option, please dial into the call five to ten minutes prior to start time using the appropriate number above and ask to join the “PacBio Q3 Earnings Call.”

PacBio 2022 Investor Day Details


Date: Tuesday, November 15, 2022 at 8:00am ET (5:00am PT)

Location: The St. Regis Hotel, Two E 55th St, New York, NY 10022

Listen via internet or replay: https://investor.pacificbiosciences.com/



2022 Financial Guidance


In light of forthcoming product announcements, we are withdrawing all prior financial guidance. We plan to provide additional information during our third quarter earnings call on November 7.


About PacBio


Pacific Biosciences of California, Inc. is a premier life science technology company that is designing, developing and manufacturing advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technology under development stem from two highly differentiated core technologies focused on accuracy, quality and completeness which include our existing HiFi long read sequencing and our emerging SBB® short read sequencing technologies. Our products address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information please visit www.pacb.com and follow @PacBio.





Forward-Looking Statements


This press release may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995, including statements relating to forthcoming product announcements and plans to provide additional information during our third quarter earnings call. You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties that could cause actual outcomes and results to differ materially from currently anticipated results. Factors that could materially affect actual results can be found in PacBio's most recent filings with the Securities and Exchange Commission, including PacBio's most recent reports on Forms 8-K, 10-K, and 10-Q, and include those listed under the caption “Risk Factors.” These forward-looking statements are based on current expectations and speak only as of the date hereof; except as required by law, PacBio disclaims any obligation to revise or update these forward-looking statements to reflect events or circumstances in the future, even if new information becomes available.





Todd Friedman




Lizelda Lopez